JOHNS HOPKINS M E D I C I N E JOHNS HOPKINS HEALTHCARE	Pharmacy Public Medical Management Drug Policies	Policy Number	MMDP070
		Effective Date	06/01/2022
		Review Date	04/20/2022
	<u>Subject</u> Provenge	Revision Date	04/20/2022
		Page	1 of 2

This document applies to the following Participating Organizations:

US Family Health Plan

Keywords: provenge

Table	e of Contents	Page Number
I.	POLICY	1
II.	POLICY CRITERIA	1
III.	AUTHORIZATION PERIOD/LIMITATIONS	1
IV.	EXCLUSIONS	1
V.	RECOMMENDED DOSAGE	1
VI.	CODES	1
VII.	REFERENCES	2
VIII.	APPROVALS	2

I. POLICY

A. Provenge (sipuleucel-T) will require prior authorization for medical benefit coverage to ensure appropriate use. The process for initiating a prior authorization request can be found in policy PHARM 20.

II. POLICY CRITERIA

- A. Provenge may be approved for patients who meet the following:
 - 1. Documentation has been provided showing the patient has been diagnosed with one of the following:
 - a. Asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer
 - b. Biochemical relapse of nonmetastatic androgen-dependent (castration-naïve) prostate cancer

III. AUTHORIZATION PERIOD/LIMITATIONS

- A. Initial approval will be limited to 6 months for a maximum of 3 doses
- B. Continuation of therapy: Approval for an additional 3-months may be provided to patients that meet the initial criteria noted above, as well as the following:
 - 1. Patient is currently receiving treatment with Provenge
 - 2. Patient has not yet completed treatment with all 3 doses

IV. EXCLUSIONS

- A. Provenge will not be covered for the following:
 - 1. More than 3 doses total
 - 2. Any indications that are not FDA-approved, or guideline-supported

V. RECOMMENDED DOSAGE

Please refer to the FDA-approved prescribing information, or clinical guidelines, for indication-specific dosing details.

VI. CODES

CPT Copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

[©] Copyright 2022 by The Johns Hopkins Health System Corporation and/or The Johns Hopkins University

MMDP070

06/01/2022

04/20/2022

04/20/2022

2 of 2


Policy Number

Effective Date

Review Date

Revision Date

Page



Note: The following CPT/HCPCS codes are included below for informational purposes. Inclusion or exclusion of a CPT/HCPCS code(s) below does not signify or imply member coverage or provider reimbursement. The member's specific benefit plan determines coverage.

Medication	HCPCS/CPT Code
Sipuleucel-t, minimum of 50 million tautologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion	Q2043

VII. <u>REFERENCES</u>

- 1. Provenge [prescribing information]. Seattle, WA: Dendreon Corporation; July 2017.
- 2. The NCCN Drugs & Biologics Compendium® © 2020 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed March 25, 2022.

VIII. APPROVALS

Signature on file at JHHC

DA	ATE OF REVISION	SUMMARY OF CHANGE
04/20/2022		Policy Creation

Review Date/s: 04/20/2022

Revision Date/s:

[©] Copyright 2022 by The Johns Hopkins Health System Corporation and/or The Johns Hopkins University